Fig 1: Effects of the knockdown of CDK4/BCAS2 on cell behaviors of esophageal cancer cells. (A) The mRNA levels of CDK4/BCAS2 in the siCDK4 and siBCAS2 EC9706 cell lines (**p<0.01). (B) Cell colony formation (**p<0.05; ***p<0.01. (C) Cell cycle (*p<0.05, **p<0.01). (D) Apoptosis (**p<0.01). (E) The expression of apoptosis related proteins.
Fig 2: Overexpression of miR-486 suppresses the expression of CDK4 and BCAS2. (A) Predicted consequential pairing of miR-486 and CDK4/BCAS2. (B) Dual-Luciferase assay (**p<0.01). (C) Expression of CDK4/BCAS2 was suppressed in the miR-486 mimic-transfected EC9706 cells (***p<0.001, **p<0.01).
Fig 3: miR-486 expression was significantly downregulated in esophageal squamous carcinoma tissues compared to that noted in the corresponding esophageal normal tissues from 20 esophageal squamous cell carcinoma patients while the expression of CDK4 and BCAS2 was upregulated. (A) The mRNA expression of miR-486, CDK4 and BCAS2 (***p<0.001). (B) Protein levels of CDK4 and BCAS2. (C) Immunohistochemical staining of CDK4 and BCAS2 in esophageal squamous carcinoma tissues and controls.
Fig 4: miR-486 expression was significantly downregulated while expression of CDK4 and BCAS2 was upregulated in esophageal cancer cell lines. (A) The mRNA expression of miR-486, CDK4 and BCAS2 (*p<0.05; **p<0.0). (B) The protein level of CDK4 and BCAS2. P<0.001 vs. controls.
Fig 5: Effects of the knockout of CDK4/BCAS2 on migration and invasion of esophageal cancer cells. (A) Migration (**p<0.01). (B) Invasion (**p<0.01).
Supplier Page from Abcam for Anti-BCAS2 antibody